Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 01/07/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6725 publications
Metabolomics to Reveal Diagnostic Biomarkers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma: A Cross-Sectional Study.
Journal: Journal of proteome research
Published: December 16, 2025
Factors Associated With Toxicity of FOLFIRINOX in Elderly Patients With Pancreatic Ductal Adenocarcinoma.
Journal: JCO oncology practice
Published: December 15, 2025
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma.
Journal: bioRxiv : the preprint server for biology
Published: December 15, 2025
Robust Machine Learning-Driven Drug Repositioning Pipeline for Classical Subtype of Pancreatic Ductal Adenocarcinoma.
Journal: Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference
Published: December 03, 2025
Serum MicroRNA-196, -200 and -423 Improve Diagnostics and Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.
Journal: Physiological research
Published: December 02, 2025
Corrigendum to "Anti-tumor activity of antibody drug conjugate targeting aspartate-β-hydroxylase in pancreatic ductal adenocarcinoma" [Cancer Lett. 449 (2019) 87-98].
Journal: Cancer letters
Published: November 26, 2025
ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma.
Journal: Annals of surgical oncology
Published: November 25, 2025
Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
ASO Visual Abstract: Evaluating Tumor Regression and Survival Outcomes in Pancreatic Ductal Adenocarcinoma After Neoadjuvant Treatment According to CAP Grading System: Clinical Usefulness and Limitations.
Journal: Annals of surgical oncology
Published: November 22, 2025
HNF1A is a novel BRD4 target and critical for BET-inhibitor response in pancreatic ductal adenocarcinoma.
Journal: bioRxiv : the preprint server for biology
Published: November 19, 2025
A Phase I/II Study Protocol of a Novel Neoadjuvant 'PRaG' Regimen (Radiotherapy, GM-CSF, and Cadonilimab) with AG Chemotherapy to Improve Resectability in Locally Advanced Pancreatic Ductal Adenocarcinoma: The NeoPRAG Study.
Journal: Technology in cancer research & treatment
Published: November 18, 2025
Surgical decision-making after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Journal: Annals of surgical treatment and research
Published: November 17, 2025
Last Updated: 01/07/2026